Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Evaxion Biotech ( (EVAX) ).
Evaxion A/S reported new phase 2 data on April 17, 2026, showing that 86% of the vaccine targets in its personalized cancer vaccine EVX-01 triggered tumor-specific immune responses in advanced melanoma patients. The data, to be presented at the AACR Annual Meeting on April 22, 2026, also include two-year analyses indicating durable vaccine-specific immunity and a strong correlation between AI-Immunology prediction scores and immune response strength.
The phase 2 trial of EVX-01 in combination with MSD’s anti-PD-1 therapy Keytruda has already produced encouraging two-year clinical results, including a 75% objective response rate and a successfully completed one-year extension earlier this month. These findings reinforce Evaxion’s positioning as a leader in AI-driven vaccine target discovery, suggesting competitive differentiation for its platform and potential upside for stakeholders if the technology continues to translate into robust clinical outcomes.
The most recent analyst rating on (EVAX) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.
Spark’s Take on EVAX Stock
According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.
The score is driven primarily by improved capitalization but still-weak cash generation and profitability. Technicals are moderately favorable with improving momentum, while valuation remains limited by losses. Earnings-call commentary adds support via clear milestone roadmap, strong EVX-01 results, and runway into H2 2027, tempered by dilution/partnering execution risks.
To see Spark’s full report on EVAX stock, click here.
More about Evaxion Biotech
Evaxion A/S is a Denmark-based clinical-stage TechBio company that develops novel cancer and infectious disease vaccines using its proprietary AI-Immunology platform. The company’s lead asset, EVX-01, is a personalized peptide-based cancer vaccine designed for first-line treatment of advanced solid tumors, including melanoma, with each dose tailored to a patient’s unique tumor and immune profile.
Average Trading Volume: 42,985
Technical Sentiment Signal: Sell
Current Market Cap: $34.53M
For an in-depth examination of EVAX stock, go to TipRanks’ Overview page.